2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Sarcoma
4
Neoplasms
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
45
pembrolizumab
35
Fluorouracil
32
Capecitabine
31
lenvatinib
26
durvalumab
26
Leucovorin
26
Magnetic Resonance Spectroscopy
14
Irinotecan
13
Drug Therapy
13
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
Specimen Handling
11
Radiofrequency Ablation
11
130-nm albumin-bound paclitaxel
11
tislelizumab
10
pemigatinib
10
apatinib
10
Taxes
10
Radiotherapy
10
Floxuridine
10
Folfox protocol
9
Bevacizumab
9
S 1 (combination)
8
Photochemotherapy
8
Liver Transplantation
8
Cholangiopancreatography, Endoscopic Retrograde
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA